Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma

Farhad Ravandi, Jayastu Senapati, Nitin B. Jain, Nicholas J. Short, Tapan M. Kadia, Gautam Borthakur, Marina Konopleva, William G. Wierda, Xuelin Huang, Abhishek Maiti, Ghayas C. Issa, Hayley Balkin, Rebecca Garris, Alessandra Ferrajoli, Guillermo Garcia‐Manero, Yesid Alvarado, Partow Kebriaei, Elias Jabbour, Hagop M. Kantarjian